Mesothelioma Clinical Trials

Clinical trials are proficient ways to study effectiveness of new drugs and treatments in the fight against the mesothelioma. Each clinical trial has specific guidelines that need to be followed in order to qualify. Mesothelioma doctors can advise patients to find the best clinical trial and the proper one on a case by case basis.

Latest Mesothelioma Clinical Trials

Mesothelioma clinical trials are conducted to find better ways to treat, diagnose, screen and monitor the disease through research and testing. Various groups and agencies conducting clinical trials are:

• National Cancer Institute (NCI)
• National Institutes of Health (NIH)
• Department of Defense
• Department of Veterans Affairs
• Pharmaceutical Companies
• Medical Institutions

The Mesothelioma Center at the New York Presbyterian Hospital and Columbia University is recruiting patients for a new trial on innovative multimodality mesothelioma treatment with targeted radiation-therapy and chemotherapy.

Mesothelioma Clinical Trial Phases

All clinical trials are divided into different phases.

• Phase I – trials usually enroll a small number of people and the purpose is to determine the best method to administer new treatment and drug and their safe administration level. The doctor closely monitors the patient for any harmful side effects.
• Phase II- trials enroll more people to give early information on effectiveness of a new drug or procedure and also provide information about safety and benefit.
• Phase III- trials requires large number so patients and the test is either randomized that is to compare promising new drugs procedures with the current standard treatment or the patients receive either the new treatment or standard treatment.

Malignant Mesothelioma Clinical Trials

Each clinical trial has different eligibility criteria. The basic eligibility requirement for malignant mesothelioma clinical trial is the patient should be minimum 21 years with histologically verified diagnosis of malignant mesothelioma.

Malignant mesothelioma clinical trials available are:

• Phase III Study of Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Mesothelioma.
• Phase II Study of Dasatinib in Patients With Previously Treated Malignant Mesothelioma.
• Phase II Study of Cisplatin, ALIMTA (generic name Pemetrexed) and Bevacizumab for Untreated Malignant Mesothelioma.

Peritoneal Mesothelioma Clinical Trials

For peritoneal mesothelioma clinical trials the basic eligibility criteria are the histologically confirmed malignant peritoneal mesothelioma with no prior chemotherapeutic regimen and patient should be more than 18 years.

Peritoneal mesothelioma clinical trials available are:

• Phase I Study of Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis.

Pleural Mesothelioma Clinical Trials

In pleural mesothelioma the basic eligibility criteria for clinical trials are the patient should have measurable sense of disease, minimum 18 years old, able to swallow capsules or tablets and have willingness for multiple blood draws.

Pleural mesothelioma clinical trials available are:

• Phase III Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the pleura in Patients with Locally Advanced but Unresectable Malignant Pleural Mesothelioma.
• A Randomized Phase II Study of a Lung-Sparing Combined Modality Protocol for the Treatment of Malignant Pleural Mesothelioma: The Columbia Protocol.
• Phase II Study of CBP501+ Pemetrexed + Cisplatin in patients with Malignant Pleural Mesothelioma.
• Phase II Study of Pazopanib Hydrochloride in Patients With Malignant Pleural Mesothelioma.
• Phase II Randomized Study of Premetrexed Disodium Combined With Either Gemcitabine or Carboplatin in Patients With Advanced Malignant Mesothelioma of the Pleura.
• Phase II Study of AZD21717 in Patients With Unresectable Malignant Pleural Mesothelioma.

Call Us, It Is Free!

Clinical trials are a potential option to consider when deciding upon mesothelioma treatment plan and a mesothelioma patient should have a complete understanding of the trial. So, if you need more information we are always present to help you.